ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2022年06月09日 10時00分
Source:
Eisai
エーザイ、2023年3月期業績予想(IFRS)の修正に関するお知らせ
東京, 2022年06月09日 - (JCN Newswire) - 直近の業績の動向等を踏まえ、2022年5月13日に公表した2023年3月期(2022年4月1日から2023年3月31日)の業績予想を下記のとおり修正しますのでお知らせします。
1. 2023年3月期の連結業績予想数値の修正(2022年4月1日から2023年3月31日)
※ご参照
https://www.eisai.co.jp/news/2022/news202246.html
2. 修正の理由
当期において、当社が保有する一部株式について株式譲渡益10億円が発生する見込みです。加えて、当社の資本政策の一環としてグローバルな資金配分の最適化を企図し、米国の連結子会社から資金を回収するために当社が米国子会社から払込資本の払戻しを受けた結果、税務上の譲渡損失等が当社にて発生し、法人所得税が従来の想定を下回ることを見込んでいます。これらにより、当期利益を前回予想から115億円増の580億円、親会社の所有者に帰属する当期利益を前回予想から115億円増の570億円に修正します。ROE(親会社所有者帰属持分当期利益率)は7.5%を見込みます。
売上収益、営業利益については、前回予想から変更ありません。
なお、1株当たり160円の年間配当金(第2四半期末80円、期末80円)の予定に変更はありません。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2022/news202246.html
概要:エーザイ株式会社
詳細は www.eisai.co.jp をご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Xforce HEV Model Earns the Highest Rating of Five Stars in 2024 ASEAN NCAP
Apr 07, 2025 15:56 JST
MHI Establishes Branch Office in Perth, Western Australia, Focused on Decarbonization Business
Apr 07, 2025 14:40 JST
Connect Marketplace Hong Kong 2025 Concludes, Successfully Ushering in a New Era for MICE in the City
Apr 05, 2025 00:00 JST
Kirin and Hitachi begin joint research on the creation of forest-based carbon credits
Apr 04, 2025 15:56 JST
Mitsubishi Corporation Announces Corporate Strategy 2027
Apr 04, 2025 09:04 JST
SMBC and Fujitsu partner towards creation of AI-powered data analytics business
Apr 03, 2025 22:10 JST
Prideone Entertainment Announces New Post-War Film to Commemorate the 80th Anniversary of World War II's End
Apr 03, 2025 07:00 JST
"GTF Advantage" Engine Achieved FAA Type Certification
Apr 02, 2025 17:41 JST
Hitachi's New Corporate Vision: Changing the World and Future with the Power of Knowledge
Apr 01, 2025 18:46 JST
Hitachi: Strengthening Our Analytical Business to Solve Social Issues with Our Core Technologies
Apr 01, 2025 18:38 JST
Hitachi: Completion of New Production Facility for Semiconductor Manufacturing Equipment in Kasado Area
Apr 01, 2025 17:52 JST
NEC has developed technologies that enable a secure workflow for personalized cancer vaccines and has proven their capabilities
Apr 01, 2025 16:15 JST
Mitsubishi Motors Launches Miland Virtual Car Lifestyle App Service
Apr 01, 2025 14:59 JST
Mitsubishi Corporation: Development of R&D Hub "iPark Kobe" in Kobe Medical Industry City
Apr 01, 2025 14:16 JST
Eisai to Divest Rights for Pariet in China to Peak Pharma
Apr 01, 2025 13:15 JST
MHIEC Receives Order for Full Refurbishment of Waste Incineration Plant in Itoman City, Okinawa Prefecture
Apr 01, 2025 11:45 JST
MHI Concludes "Mizuho Eco Finance" Commitment Line Agreement
Apr 01, 2025 10:51 JST
MHI Concludes Nissay Positive Impact Finance Agreement
Apr 01, 2025 09:54 JST
Gome Retail Continues to Focus on Its Main Business and Actively Resolve Debt
Apr 01, 2025 02:36 JST
Cryofocus Medtech: Steady Increase in Revenue and Gross Profit with Solid R&D Expenditures in 2024
Apr 01, 2025 01:42 JST
More Latest Release >>
Related Release
Eisai to Divest Rights for Pariet in China to Peak Pharma
4/1/2025 1:15:00 PM JST
World's First Early Alzheimer's Disease Treatment Developed in Japan LEQEMBI Receives Prime Minister's Award at the 12th Technology Management and Innovation Awards
3/25/2025 5:28:00 PM JST
Eisai Selected as a Nadeshiko Brand 2025 as a Listed Company Excelling in Promotion of Women in the Workplace
3/25/2025 12:21:00 PM JST
Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time
3/10/2025 8:24:00 PM JST
Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan
3/5/2025 9:09:00 AM JST
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia
3/4/2025 5:22:00 PM JST
"Fatigue Recovery While You Sleep!" Eisai to Launch Designated Quasi-Drug Drink "Chocola BB Nightwell"
3/3/2025 3:41:00 PM JST
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease
3/3/2025 1:53:00 PM JST
Eisai Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone
2/28/2025 12:31:00 PM JST
Eisai Selected for "Human Capital Leaders 2024" and "Human Capital Management Gold Quality" for Second Consecutive Year, as a Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
2/20/2025 1:29:00 PM JST
More Press release >>